Medpace (NASDAQ:MEDP) Trading Up 0.2%

Medpace Holdings, Inc. (NASDAQ:MEDP)’s share price was up 0.2% during trading on Thursday . The stock traded as high as $388.78 and last traded at $388.38. Approximately 37,699 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 246,536 shares. The stock had previously closed at $387.61.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MEDP. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and increased their price objective for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 price target on the stock. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. Robert W. Baird boosted their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Finally, Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and boosted their price target for the company from $340.00 to $450.00 in a report on Tuesday, April 23rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Stock Performance

The stock has a market capitalization of $12.37 billion, a P/E ratio of 40.69, a P/E/G ratio of 1.95 and a beta of 1.40. The stock has a 50 day moving average of $397.69 and a 200 day moving average of $334.57.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The firm had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same period in the prior year, the business earned $2.27 EPS. The firm’s revenue was up 17.7% on a year-over-year basis. On average, research analysts anticipate that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Medpace Investors, Llc sold 13,988 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total value of $5,404,823.32. Following the completion of the transaction, the insider now directly owns 5,525,959 shares of the company’s stock, valued at approximately $2,135,175,298.01. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO August J. Troendle sold 25,000 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $408.71, for a total transaction of $10,217,750.00. Following the completion of the sale, the chief executive officer now directly owns 4,733,019 shares of the company’s stock, valued at approximately $1,934,432,195.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the sale, the insider now directly owns 5,525,959 shares of the company’s stock, valued at $2,135,175,298.01. The disclosure for this sale can be found here. Insiders have sold a total of 204,442 shares of company stock valued at $82,702,867 in the last three months. Insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Medpace by 2.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock valued at $2,114,000 after buying an additional 148 shares during the last quarter. Portside Wealth Group LLC boosted its position in shares of Medpace by 14.8% in the 4th quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock worth $435,000 after purchasing an additional 183 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Medpace by 355.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock worth $1,090,000 after acquiring an additional 2,774 shares in the last quarter. Norden Group LLC increased its position in shares of Medpace by 207.8% during the 4th quarter. Norden Group LLC now owns 5,014 shares of the company’s stock worth $1,537,000 after purchasing an additional 3,385 shares during the last quarter. Finally, Retirement Systems of Alabama increased its position in shares of Medpace by 0.3% during the 4th quarter. Retirement Systems of Alabama now owns 62,106 shares of the company’s stock worth $19,037,000 after purchasing an additional 204 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.